ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer

BACKGROUND: Immunotherapy with checkpoint inhibitors (CPI) targeting PD-1 or CTLA-4 has emerged as an important treatment modality for several cancer forms. In hormone receptor positive breast cancer (HR + BC), this therapeutic approach is largely unexplored. We have started a clinical trial, ICON (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyte, J. A., Andresen, N. K., Russnes, H. G., Fretland, S. Ø., Falk, R. S., Lingjærde, O. C., Naume, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333428/
https://www.ncbi.nlm.nih.gov/pubmed/32620163
http://dx.doi.org/10.1186/s12967-020-02421-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333428/
https://www.ncbi.nlm.nih.gov/pubmed/32620163
http://dx.doi.org/10.1186/s12967-020-02421-w

Ejemplares similares